ArticleFrontiers in neurology2025
Efficacy of intratympanic methylprednisolone versus standard therapy in adult sudden sensorineural hearing loss.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sudden sensorineural hearing loss (SSNHL) is a medical emergency that can significantly impact quality of life. The study aimed to compare the efficacy and safety of intratympanic methylprednisolone therapy (IMT) with standard treatment (ST) in adult patients suffering from unilateral SSNHL. Methods: A retrospective analysis was conducted on 300 adult patients diagnosed with unilateral SSNHL, treated at our hospital from June 2022 to November 2024. Patients were divided into two groups based on their treatment protocols: IMT group (142 patients) and ST group (158 patients). All patients completed 1 year of follow-up. Outcomes were assessed via pure tone average (PTA), word recognition score (WRS), tinnitus/dizziness resolution, and quality of life (SF-36). Results: The IMT group showed significantly greater improvement in PTA and WRS at both follow-up points compared to the ST group ( Conclusion: IMT demonstrated superior efficacy and an acceptable safety profile compared to ST for adult patients with unilateral SSNHL, suggesting it as a preferable therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.